ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.

Oscar L. Morey-Vargas, Victor M. Montori

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)JC8-9
JournalUnknown Journal
Issue number2
StatePublished - Jan 21 2014

ASJC Scopus subject areas

  • Internal Medicine

Cite this